Cabaletta Bio Company Insiders
| CABA Stock | USD 3.19 -0.08 -2.45% |
Cabaletta Bio's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Cabaletta Bio suggests that virtually all insiders are extremely bullish. Cabaletta Bio employs about 148 people. The company is managed by 13 executives with a total tenure of roughly 346 years, averaging almost 26.0 years of service per executive, having 11.38 employees per reported executive.
Insider Sentiment
Aggressively Buying
Selling | Buying |
Latest Trades
| 2026-01-21 | Steven Nichtberger | Acquired 45000 @ 2.24 | View |
Following insider trading sentiment in Cabaletta Bio can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Cabaletta | Build AI portfolio with Cabaletta Stock |
Cabaletta Bio's Workforce Through the Years
A workforce review of Cabaletta Bio matters because hiring and staffing trends often say something about growth plans, cost discipline, and management expectations. Current projections suggest a workforce around about 150 employees by April 2026, which should be reviewed alongside revenue and margin trends.Macro event markers
Cabaletta Bio Management Team Effectiveness
The company has return on total asset (ROA) of -51.82 % which means that on every $100 spent on assets, it lost $51.82. This is very low relative to industry peers. Similarly, it shows a return on stockholder's equity (ROE) of -101.06 %, which implies that shareholder value decreased during the period.This year, Common Stock Shares Outstanding is anticipated to decline to approximately 29.2 M. In addition to that, Net Loss is expected to increase toward approximately -45.3 M
Stock Ownership Analysis
About 79.0% of the company shares are held by institutions such as insurance companies. The book value of Cabaletta Bio was currently reported as 1.45. The company recorded a loss per share of 2.4. Cabaletta Bio had not issued any dividends in recent years.Stock Institutional Investors
Institutional ownership matters in Cabaletta Bio because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Marshall Wace Asset Management Ltd | 2025-09-30 | 1.3 M | T. Rowe Price Associates, Inc. | 2025-09-30 | 1.3 M | Woodline Partners Lp | 2025-12-31 | 1.3 M | Schonfeld Strategic Advisors Llc | 2025-12-31 | 1.2 M | Jpmorgan Chase & Co | 2025-09-30 | 1.1 M | Geode Capital Management, Llc | 2025-09-30 | 920.3 K | Opaleye Management Inc | 2025-12-31 | 900 K | Schroder Investment Management Group | 2025-12-31 | 756.6 K | Two Sigma Advisers, Llc | 2025-12-31 | 737.9 K | Bain Capital Life Sciences Investors, Llc | 2025-12-31 | 9.7 M | Jennison Associates Llc | 2025-12-31 | 8.9 M |
Insider Trading Activities
Insider trading disclosures for Cabaletta Bio offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 307.09 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Outstanding Bonds
Reviewing Cabaletta Bio bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 61.9 M | Current Value 102.3 M | Average Shares Outstanding 31.8 M | Quarterly Volatility 19.9 M |
Macro event markers
Cabaletta Stock Holders Distribution
Institutional ownership analysis for Cabaletta Bio matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Cabaletta Bio Workforce Comparison
Cabaletta Bio is rated below average in number of employees among leading competitors. The total workforce of Health Care industry is currently estimated at about 1,550. Cabaletta Bio holds roughly 148 in number of employees claiming about 10% of equities under Health Care sector.
Cabaletta Bio Insider Trading History
Insider trading disclosures for Cabaletta Bio offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 307.09 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-06-01 | 0.9231 | 48 | 52 | 5,122,360 | 5,366,360 |
| 2024-03-01 | 2.3333 | 7 | 3 | 954,000 | 22,000 |
| 2023-12-01 | 0.3333 | 3 | 9 | 33,000 | 66,000 |
| 2023-09-01 | 0.4444 | 4 | 9 | 77,000 | 66,000 |
| 2023-06-01 | 1.5 | 6 | 4 | 121,000 | 66,000 |
| 2022-03-01 | 1.75 | 7 | 4 | 1,035,000 | 132,584 |
| 2021-09-01 | 1.0 | 1 | 1 | 100,000 | 625,000 |
| 2021-06-01 | 5.0 | 5 | 1 | 132,000 | 22,000 |
| 2021-03-01 | 1.25 | 5 | 4 | 736,500 | 387,000 |
| 2020-12-01 | 0.5 | 1 | 2 | 93,226 | 298,000 |
| 2019-12-01 | 0.6 | 12 | 20 | 5,946,670 | 7,893,533 |
Cabaletta Bio Notable Stakeholders
Stakeholders matter for Cabaletta Bio because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Gwendolyn Binder | President Technology | Profile | |
| PharmD MBA | SVP International | Profile | |
| Samik MD | Chief Officer | Profile | |
| Aimee MD | CoFounder Board | Profile | |
| Arun MD | Chief Officer | Profile | |
| Anup MBA | Chief Officer | Profile | |
| SPHR CCP | Chief Officer | Profile | |
| Steven MD | Chairman, CoFounder | Profile | |
| FACR MD | Chief Officer | Profile | |
| Michael JD | General Secretary | Profile | |
| Heather MSc | Chief Officer | Profile | |
| Qing Yuan | Chief Officer | Profile | |
| Martha OConnor | Chief Officer | Profile |
Management Information & Data Sources
Cabaletta Bio is a small-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Executive turnover can affect operating consistency and long-range planning. Cabaletta Bio employs 148 people.
Data shown for Cabaletta Bio is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Analyst inputs may be included when coverage is available. Source publication cadence can introduce delays. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Vlad Skutelnik - Macroaxis ContributorWorkforce Efficiency and Productivity
Investors reviewing Cabaletta Bio can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Cabaletta Bio Manpower Efficiency
Return on Cabaletta Bio Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 782.9K | |
| Net Loss Per Executive | 8.9M | |
| Working Capital Per Employee | 943.2K | |
| Working Capital Per Executive | 10.7M |
Popular Tools for Cabaletta Stock analysis
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |